|
| Thursday, December 11, 2025 |
|
|
エーザイ、CDP より「気候変動」「水セキュリティ」分野で最高評価 A リストに 2 年連続でダブル選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、国際的な環境非営利団体 CDP1より 2025 年の「気候変動」および「水セキュリティ」分野において、最高評価である A リストに選定されましたのでお知らせします。2 年連続での両分野における A リストへのダブル選定となります。 more info >> |
|
| Thursday, December 4, 2025 |
|
|
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025 |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI(R)) were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. more info >> |
|
| Wednesday, December 3, 2025 |
|
|
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest data confirming the pharmacological effect of lecanemab, an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. more info >> |
|
| Tuesday, December 2, 2025 |
|
|
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at the 18th Clinical Trials on Alzheimer's Disease Conference (CTAD). more info >> |
|
| Friday, November 28, 2025 |
|
|
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has filed a new drug application for "LEQEMBI(R)" (brand name, generic name: lecanemab) seeking approval for a subcutaneous formulation (subcutaneous autoinjector: SC-AI) as a new route of administration to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). more info >> |
|
| Wednesday, November 26, 2025 |
|
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. more info >> |
|
| Monday, November 17, 2025 |
|
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. more info >> |
|
| Thursday, October 30, 2025 |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| more info >> |
|
| Tuesday, October 28, 2025 |
|
|
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma |
| more info >> |
|
| Monday, October 27, 2025 |
|
|
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease |
| more info >> |
|
|
|
|
